Revvity (RVTY) official guidance

We also still expect our diluted average share count to continue to be approximately 112 million.

Lastly, given our significant share repurchase activity throughout 2025, we expect our diluted average share count to be approximately 112 million in 2026.

Our outlook for net interest expense and other is now approximately $90 million, and we continue to anticipate our adjusted tax rate for the full year will be approximately 18%.

Consequently, we are assuming an 18% adjusted tax rate in our initial 2026 guidance, up from the 14.5% we ultimately generated last year.

For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.83-$2.86 billion, pro forma organic revenue growth of 4-5%, and pro forma adjusted earnings per share of $5.30-$5.40.

As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3%-4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20-$5.30, which includes a 20% reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution throughout the year.

For the full year 2026, on a pro forma basis, the Company forecasts total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted earnings per share of $5.20-$5.30.

We expect this all to result in our 2026 adjusted earnings per share to be in the range of $5.35-$5.45, representing high single-digit adjusted EPS growth for the year.

For the full year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%, and adjusted earnings per share of $5.35-$5.45.

Our outlook for net interest expense and other is now approximately $90 million, and we continue to anticipate our adjusted tax rate for the full year will be approximately 18%.

Because we will lose this currently favorable spread on our cash versus this low-cost debt and also have lower average cash balances as a result of our 2025 share repurchases, we anticipate our net interest expense and other to be approximately $95 million this year, up from $84 million in 2025.

As it pertains to our updated pro forma guidance for 2026, which now excludes the immunodiagnostics business in China, we are now looking for organic growth of 3%-4%, adjusted operating margins of 28.4%, and adjusted earnings per share of $5.20-$5.30, which includes a 20% reduction related to the planned divestiture, offset by $0.05 of benefit from improved operational execution throughout the year.

While their impact will increase as the year goes on, especially in the second half of the year, we continue to expect these initiatives to result in our adjusted operating margins this year being 28% overall.

Within the 2%-3% growth scenario, we also remain confident with our 28% adjusted operating margin baseline expectation for next year, given the restructuring activities that are already well underway.

When you look between the jump of 2Q-3Q, we do expect our margins to go up about from 27% in the second quarter to 29% in the third quarter.

Consequently, while Max will provide more details in a bit, we are reiterating for our organic growth this year to be in the 2%-3% range, as we are assuming recent end market trends continue over the course of the year.

As we view our markets today, our best and most prudent assumption for next year is that organic growth continues to remain similar to what it has been over the last several years in the 2%-3% range, but we see opportunity for improvements once customers consistently return to more historically normal levels of spending.

You know, I think it's, just to answer your question on what that looks like, for the rest of the full year, there's been really no change in our assumption to it contributing about $20 million for us in the first year. Obviously for this year.